Compare Stocks: PYXS, MNPR, CADL, and DRUG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.80 +2.8%	$9.30	$4.35 ▼ $11.36	$791.32M	-0.51	1.54 million shs	88,197 shs
DRUG Bright Minds Biosciences	$78.07 +0.9%	$70.81	$33.96 ▼ $123.75	$759.62M	-5.27	232,726 shs	2,594 shs
MNPR Monopar Therapeutics	$116.41 -1.7%	$87.54	$29.18 ▼ $120.28	$779.95M	1.47	219,703 shs	18,971 shs
PYXS Pyxis Oncology	$3.27 +3.5%	$2.31	$0.97 ▼ $5.55	$207.15M	1.31	768,182 shs	89,052 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+4.37%	+8.57%	+6.92%	+37.75%	+66.56%
DRUG Bright Minds Biosciences	+4.84%	+7.49%	+14.42%	-12.99%	+118.07%
MNPR Monopar Therapeutics	+6.11%	+8.59%	+21.14%	+85.50%	+183.74%
PYXS Pyxis Oncology	+3.95%	+8.59%	+20.15%	+37.39%	+187.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.80 +2.8%	$9.30	$4.35 ▼ $11.36	$791.32M	-0.51	1.54 million shs	88,197 shs
DRUG Bright Minds Biosciences	$78.07 +0.9%	$70.81	$33.96 ▼ $123.75	$759.62M	-5.27	232,726 shs	2,594 shs
MNPR Monopar Therapeutics	$116.41 -1.7%	$87.54	$29.18 ▼ $120.28	$779.95M	1.47	219,703 shs	18,971 shs
PYXS Pyxis Oncology	$3.27 +3.5%	$2.31	$0.97 ▼ $5.55	$207.15M	1.31	768,182 shs	89,052 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+4.37%	+8.57%	+6.92%	+37.75%	+66.56%
DRUG Bright Minds Biosciences	+4.84%	+7.49%	+14.42%	-12.99%	+118.07%
MNPR Monopar Therapeutics	+6.11%	+8.59%	+21.14%	+85.50%	+183.74%
PYXS Pyxis Oncology	+3.95%	+8.59%	+20.15%	+37.39%	+187.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.60	Moderate Buy	$18.57	71.96% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	84.24% Upside
MNPR Monopar Therapeutics	3.07	Buy	$112.08	-3.72% Downside
PYXS Pyxis Oncology	2.70	Moderate Buy	$7.50	129.36% Upside

Current Analyst Ratings Breakdown

Latest PYXS, MNPR, CADL, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/23/2026	MNPR Monopar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$125.00
7/22/2026	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $125.00
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	MNPR Monopar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/13/2026	CADL Candel Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
7/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
PYXS Pyxis Oncology	$13.86M	14.95	N/A	N/A	$0.86 per share	3.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$0.98	N/A	N/A	N/A	N/A	-60.42%	-41.33%	8/13/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	8/13/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$1.90	N/A	N/A	N/A	N/A	-12.84%	-12.57%	8/11/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.31	N/A	N/A	N/A	N/A	-135.60%	-85.00%	8/13/2026 (Estimated)

Latest PYXS, MNPR, CADL, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.34	N/A	N/A	N/A	$0.03 million	N/A
8/11/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.67	N/A	N/A	N/A	N/A	N/A
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A
5/14/2026	Q1 2026	CADL Candel Therapeutics	-$0.2958	-$0.14	+$0.1558	-$0.14	N/A	N/A
5/14/2026	Q1 2026	MNPR Monopar Therapeutics	-$0.8703	-$0.46	+$0.4103	-$0.46	N/A	N/A
5/14/2026	Q1 2026	PYXS Pyxis Oncology	-$0.35	-$0.37	-$0.02	-$0.37	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.34	28.05	28.05
DRUG Bright Minds Biosciences	N/A	81.47	81.47
MNPR Monopar Therapeutics	N/A	56.04	56.04
PYXS Pyxis Oncology	N/A	2.76	2.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DRUG Bright Minds Biosciences	40.52%
MNPR Monopar Therapeutics	1.83%
PYXS Pyxis Oncology	39.07%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
DRUG Bright Minds Biosciences	42.66%
MNPR Monopar Therapeutics	9.70%
PYXS Pyxis Oncology	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	73.27 million	62.79 million	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
MNPR Monopar Therapeutics	10	6.70 million	6.05 million	Not Optionable
PYXS Pyxis Oncology	60	63.35 million	59.74 million	Optionable

PYXS, MNPR, CADL, and DRUG Headlines

Recent News About These Companies

Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company

August 4 at 5:59 AM | marketbeat.com

Guggenheim Sticks to Its Buy Rating for Pyxis Oncology (PYXS)

July 22, 2026 | theglobeandmail.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts

July 21, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR)

July 16, 2026 | theglobeandmail.com

Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin

July 15, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Glaukos (GKOS)

July 12, 2026 | theglobeandmail.com

Pyxis Oncology Raises Capital Through Private Placement Financing

July 3, 2026 | theglobeandmail.com

Pyxis Oncology Secures $50 Million Private Placement to Extend Cash Runway and Fund MICVO Clinical Development

June 30, 2026 | quiverquant.comQ

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

June 30, 2026 | globenewswire.com

Pyxis Oncology Announces Interim CEO Amid Leadership Transition

June 24, 2026 | theglobeandmail.com

Pyxis Oncology Stockholders Approve Directors and Auditor Slate

June 15, 2026 | tipranks.com

Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)

June 10, 2026 | insidermonkey.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)

May 19, 2026 | theglobeandmail.com

Pyxis Oncology (PYXS) Gets a Buy from Guggenheim

May 17, 2026 | theglobeandmail.com

Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility

May 15, 2026 | tipranks.com

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

May 14, 2026 | globenewswire.com

Pyxis Oncology to Participate in Upcoming Investor Conferences

May 13, 2026 | globenewswire.com

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

May 7, 2026 | globenewswire.com

Wedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendation

May 5, 2026 | msn.com

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

April 17, 2026 | globenewswire.com

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

March 26, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, MNPR, CADL, and DRUG Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.80 +0.29 (+2.76%)

As of 09:58 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$78.07 +0.72 (+0.93%)

As of 09:45 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Monopar Therapeutics NASDAQ:MNPR

$116.41 -2.05 (-1.73%)

As of 09:57 AM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Pyxis Oncology NASDAQ:PYXS

$3.27 +0.11 (+3.48%)

As of 09:57 AM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, MNPR, CADL, and DRUG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, MNPR, CADL, and DRUG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, MNPR, CADL, and DRUG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, MNPR, CADL, and DRUG Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Monopar Therapeutics NASDAQ:MNPR

Pyxis Oncology NASDAQ:PYXS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, MNPR, CADL, and DRUG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, MNPR, CADL, and DRUG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, MNPR, CADL, and DRUG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, MNPR, CADL, and DRUG Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Monopar Therapeutics NASDAQ:MNPR

Pyxis Oncology NASDAQ:PYXS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools